Análisis Argos
RGEN
RGENCara
Repligen Corporation · Healthcare
US$ 142.40
precio al 2026-07-04
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
41/100
LA RESPUESTA
El mercado le pide crezca 60% al año — más de lo que ha demostrado (3.2%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
Sin recompensas destacadas.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
VALOR1/6FUTURO5/6PASADO3/6SALUD3/6DIVIDENDO1/6
El Iris de calidad
VALOR1/6FUTURO5/6PASADO3/6SALUD3/6DIVIDENDO1/6
ValorCotiza por encima de su valor justo
FuturoIngresos creciendo con fuerza
PasadoHistorial aceptable
SaludBalance razonable
DividendoEl dividendo aún duerme
Score Argos41de 100Cara
Ingresos▲17%
US$ 0.7 B
Margen operativo▼247%
8.1%
Flujo de caja libre▼36%
US$ 0.1 B
Deuda neta
US$ 0.1 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 8.0B
P/E164.3x
EV/EBITDA59x
FCF yield1.2%
ROIC2.1%
Margen operativo8.1%
Crecim. ingresos+16.4%/año
Piotroski F7/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

gurufocus.com · 22 jun
Repligen Corp (RGEN) Shares Fall 4.1% -- What GF Score of 83 Tells Investors
On June 22, 2026, Repligen Corp (RGEN) shares fell 4.1% today, bringing the current price to $126.67. The stock has seen a 52-week range of $100.99 to $175.77,
gurufocus.com · 9 jun
Repligen Corp (RGEN) Shares Surge 3.8% -- What GF Score of 83 Tells Investors
On June 09, 2026, Repligen Corp (RGEN) shares rose 3.8% today, closing at $130.10. The stock has fluctuated within a 52-week range of $100.99 to $175.77, indica
zacks.com · 4 jun
Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
seekingalpha.com · 4 jun
Alger SICAV - Alger Small Cap Focus Fund Q1 2026 Portfolio Update
During the first quarter of 2026, the largest portfolio sector weightings were Health Care and Industrials. RBC Bearings Incorporated, Cognex Corporation and Nebius Group were among the top contributors to performance. Repligen Corporation, Agilysys, Inc., and GeneDx Holdings Corp. were among the top detractors from performance.
seekingalpha.com · 3 jun
Repligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Repligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference Transcript
seekingalpha.com · 31 may
Repligen Has A Cleaner Recovery Angle, But With High Valuation
Repligen Has A Cleaner Recovery Angle, But With High Valuation
gurufocus.com · 28 may
Repligen Corp (RGEN) Stock Up 8.4% and Still Undervalued -- GF Score: 79/100
On May 28, 2026, Repligen Corp (RGEN) shares rose 8.4% today, bringing the current price to $122.73. The stock has experienced volatility over the past year, tr
globenewswire.com · 22 may
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
WALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the William Blair 46th Annual Growth Stock Conference in Chicago, IL. Olivier Loeillot, President and Chief Executive Officer, will present a company overview on June 3rd at 10:40 a.m. CT.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.